OntologiesncitclassesNCIT:C65220   
JSON document
Alefacept
http://purl.obolibrary.org/obo/NCIT_C65220

A recombinant dimeric fusion protein consisting of the extracellular CD2-binding domain of the human leukocyte function-associated antigen 3 (LFA-3; CD58) linked to the Fc portion of human immunoglobulin G1 (IgG1) with potential immunosuppressive activity. Alefacept binds to the CD2 receptor expressed on the majority of T lymphocytes, blocking the binding of endogenous LFA-3, located on antigen-presenting cells (APCs), to the CD2 receptor; the activation and proliferation of T lymphocytes in response to LFA-3 binding is thus inhibited. In addition, binding of the IgG1 moiety of this agent to the Fc gamma receptor on the surface of natural killer (NK)cells may bridge NK cells and target T lymphocytes, initiating NK cell-mediated apoptosis of T lymphocytes.

Exact Synonyms
alefacept
Alefacept
ALEFACEPT
Amevive
LFA3TIP
class Information
ALT_DEFINITION

A drug that is used to treat certain skin conditions and is being studied in the treatment of cutaneous (skin-related) T-cell cancer and T-cell non-Hodgkin lymphoma. Alefacept is made by combining part of an antibody with a protein that blocks the growth some types of T cells. It is a type of fusion protein and a type of immunosuppressant.

CAS_Registry

222535-22-0

code

C65220

Contributing_Source
  • CTRP
  • FDA
  • GDC
Display_Name

Alefacept

FDA_UNII_Code

ELK3V90G6C

Is_Value_For_GDC_Property

Pharmacologic Substance

Legacy Concept Name

Alefacept

Maps_To

Alefacept

NCI_Drug_Dictionary_ID

531798

PDQ_Closed_Trial_Search_ID

531798

PDQ_Open_Trial_Search_ID

531798

Preferred_Name

Alefacept

Semantic_Type

Pharmacologic Substance

UMLS_CUI

C0962603

class Relations